Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity
Authors:
- 1 April 2017
- journal article
- Published by Elsevier in Cancer/Radiothérapie
- Vol. 21 (2) , 114-118
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Oncology, 2013
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab TherapyJournal of Clinical Oncology, 2010
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor ModelsCancer Research, 2009
- Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?Targeted Oncology, 2009
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineThe Oncologist, 2009
- Breast Cancer With Synchronous Metastases: Survival Impact of Exclusive Locoregional RadiotherapyJournal of Clinical Oncology, 2009
- Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast CancerClinical Cancer Research, 2008
- Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCancer Immunology, Immunotherapy, 2005
- The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer CellsCancer Research, 2004